Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Alfresa Sets Up Regenerative Medicine Unit to Supply Master Cells, Eyes Distribution
Major wholesaler Alfresa has established a new subsidiary dedicated to regenerative medicine products. A cell culture and processing facility is now being built with the aim of supplying master cells to support drug makers that develop regenerative medicine products. The…
To read the full story
Related Article
- Cell Resources Launches Umbilical Cord- and Amnion-Derived MSCs
July 15, 2026
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
- Alfresa to Build New Cell Therapy CDMO Site in Japan
March 4, 2025
BUSINESS
- Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
- Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
August 4, 2026
- Shionogi Highlights ViiV’s Long-Term HIV IP Strategy
August 4, 2026
- Kyowa Kirin Profits Surge as R&D Costs Fall, Overseas Sales Grow
August 4, 2026
- Kyorin to Begin Co-Promoting Alesion Eyelid Cream on August 17
August 4, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…